Brilliant blue G-250
(Synonyms: 酸性蓝90,Acid Blue 90,CBBG,Coomassie Brilliant Blue G-250,NSC 328382) 目录号 : GC12421A dye for staining or quantifying proteins
Cas No.:6104-58-1
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Brilliant Blue G is also a selective inhibitor of the P2X purinoceptor channel P2X7 [1].
P2X receptors are membrane ion channels activated in response to the binding of extracellular ATP. Seven P2X subtypes have been identified. P2X receptors have been involved in in diverse patho- and physiological processes, such as the autonomic nervous system, afferent signalling, chronic pain, and in autocrine loops of endothelial and epithelial cells. The P2X7 receptor plays a prominent role in certain neurologic disorders, such as ischemia-reperfusion injury, Alzheimer's disease, spinal cord injury and sensory neuropathies [2].
In HEK293 cells heterologously expressing human P2X7 receptors, Brilliant Blue G noncompetitively inhibited rat and human P2X7 receptors with IC50 values of 10 and 200 nM, respectively. The IC50 values for inhibition of the other P2X receptors ranged from 2 to >30 μM; Brilliant Blue G inhibited the rat and human P2X4 receptors with the IC50 values of >10 and 3.2 μM [1]. Subretinal injection of BBG caused retinal cell degeneration at lower concentrations. Subretinal injection of BBG (0.25 mg/mL) provided satisfactory biocompatibility [3].
References:
[1] Jiang L H, Mackenzie A B, North R A, et al. Brilliant blue G selectively blocks ATP-gated rat P2X7 receptors[J]. Molecular pharmacology, 2000, 58(1): 82-88.
[2] Sperlágh B, Vizi E S, Wirkner K, et al. P2X 7 receptors in the nervous system[J]. Progress in neurobiology, 2006, 78(6): 327-346.
[3] Ueno A, Hisatomi T, Enaida H, et al. Biocompatibility of brilliant blue G in a rat model of subretinal injection[J]. Retina, 2007, 27(4): 499-504.
Cas No. | 6104-58-1 | SDF | |
别名 | 酸性蓝90,Acid Blue 90,CBBG,Coomassie Brilliant Blue G-250,NSC 328382 | ||
化学名 | N-[4-[[4-[(4-ethoxyphenyl)amino]phenyl][4-[ethyl[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylene]-3-methyl-2,5-cyclohexadien-1-ylidene]-N-ethyl-3-sulfo-benzenemethanaminium, sodium salt | ||
Canonical SMILES | CC1=CC(N(CC)CC2=CC=CC(S(=O)([O-])=O)=C2)=CC=C1/C(C3=CC=C(NC4=CC=C(OCC)C=C4)C=C3)=C5C=C/C(C=C\5C)=[N+](CC6=CC=CC(S(=O)([O-])=O)=C6)/CC.[Na+] | ||
分子式 | C47H48N3O7S2 • Na | 分子量 | 854 |
溶解度 | ≥ 21.35mg/mL in DMSO | 储存条件 | Store at RT |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.171 mL | 5.8548 mL | 11.7096 mL |
5 mM | 0.2342 mL | 1.171 mL | 2.3419 mL |
10 mM | 0.1171 mL | 0.5855 mL | 1.171 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。